Navigation Links
TPI Reports Second Quarter Fiscal Year 2013 Financial Results
Date:2/14/2013

that continued pricing pressures in our marketplace shall remain for the second half of fiscal 2013 amid ongoing healthcare reform in China which may continue to put pressure on our revenue growth for the year. Yet we expect that JCM and TMT distribution business may help TPI to offset these external pressures to deliver 2013 revenue growth of approximately 10% to 15%. We reiterate our fiscal 2013 revenue projection of approximately $75 to $80 million along with a net margin of approximately 10%.

We believe the following factors will influence the growth perspectives of TPI: 1) Market expansion and revenue growth of TPI's core product portfolio led by flagship product GMOL, Azithromycin and other major products; 2) Ramp up of JCM revenue in the fiscal year 2013; 3) The gradual stabilization of generic sales following the progressive pricing restrictions as a result of the ongoing healthcare reform; 4) Steady TMT distribution revenue contribution; and 5) QLF relocation and smooth transition of production capacity.Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.

Conference CallSenior management of TPI will host its earnings conference call for the second quarter of fiscal year 2013 ending December 31, 2012 to be held at 8:30 a.m. ET on Thursday, February 14, 2013.

Interested parties may access the call by dialing toll free: 1-877-941-2068; international: 1-480-629-9712

The conference ID is 4594892. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling toll free: 1-877-870-5176; international: 1-858-384-5517 from: 02/14/13 @ 11:30 am ET to: 02/28/13 @ 11:59 pm ET. Replay Pin Number: 4594892

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.v
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
2. Hanger Reports $0.62 Diluted EPS for the Fourth Quarter 2012
3. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
4. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
5. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
6. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
7. Allied Healthcare Products Reports Second Quarter Loss
8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
9. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
10. Misonix Reports Financial Results for First Half of Fiscal 2013
11. CareFusion Reports First Half Fiscal 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Inc. has initiated Phase I/II clinical studies with ... Phase I/II safety and tolerability study in 18 ... cancer has begun,enrolment in the US. Secondary objectives ... vaccine to induce prostate antigen-specific immune,responses, as well ...
... of Clinical Oncology meeting indicate ... data., PRINCETON, N.J., June 3 Celator ... clinical trial in patients,with advanced colorectal cancer. CPX-1 ... on the company,s proprietary,CombiPlex(TM) technology. The results were ...
Cached Medicine Technology:BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:5/28/2015)... Recently, KORT Richmond, 5006 Atwood Drive, added a new therapy ... The program works with those new to prosthetic devices and ... still having difficulty. , According to the Amputee Coalition ... loss in the United States. The main causes of amputation ... disease – trauma (45%) and cancer (less than 2%), according ...
(Date:5/28/2015)... 28, 2015 Cosmetic Town Journal is ... and patients alike. You can find information on a ... body contouring. Readers can directly connect to the doctor ... from the ground up. , The continued addition of ... community to grow and getting it closer to becoming ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 The USC ... outpatient wound center management for a decade with a current ... was formed between USC and Wound Care Advantage to provide ... recognized for a drop in the rate of ... , Wound healing is a complex undertaking that can frighten ...
(Date:5/28/2015)... AMVETS National Executive Director Stewart Hickey has ... established by Congress to examine how to best deliver ... the commission by Mitch McConnell, majority leader of the ... 15 voting members on the panel, which was established ... 2014. The goal of the commission is to examine ...
(Date:5/28/2015)... 2015 The Clinical Data Interchange ... the International Organization for Standardization (ISO) now recognizes ... Model version 3.2 as a published, Final International ... healthcare. This standard, which had previously passed through ... unanimously approved on 24 April for publication by ...
Breaking Medicine News(10 mins):Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 3Health News:USC Verdugo Hills Hospital Wound Care Team Provides Outstanding Healing Results 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3
... HUM ) has,recently released three of its Stay Smart, Stay Healthy ... Stay Healthy videos have racked up more than 1.1 million,hits on ... remained,in the Top 5 videos in education worldwide through December. The ... , "We developed the Stay Smart, Stay ...
... the DNC bolsters firm,s national government affairs practiceWASHINGTON, ... nationally recognized political figure, presidential candidate and six ... an independent consultant exclusive to the government affairs ... Governor Dean will provide guidance to clients, particularly ...
... Than Half of America,s Youth Exceed Recommended Fat Intake; ... Makeover QUINCY, Mass., March 3 Continuing its tradition ... has expanded its NutriFilter sorting feature to include ... program recently launched at sister companies, Stop & ...
... genders regardless of weight issues, study finds , , TUESDAY, March ... than two hours a day or are otherwise inactive have ... , Researchers looked at more than 3,000 children whose ... age. , Each year, parents were asked about any ...
... Each day we have countless conversations with ourselves, and if ... what we say to ourselves is critical, judgmental, and often ... get it, we tend to make excuses and blame others, ... to our assumed shortcomings. Carol Messmer,s new ...
... 3 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ... develops and commercializes prescription drugs for the treatment of ... product development program. In order to extend its ... halt enrollment of new subjects into its ongoing U.S. ...
Cached Medicine News:Health News:Humana Releases Stay Smart, Stay Healthy Videos in Spanish 2Health News:Howard Dean to Join McKenna Long and Aldridge LLP 2Health News:Howard Dean to Join McKenna Long and Aldridge LLP 3Health News:Peapod Expands NutriFilter Shopping Tool With Healthy Ideas Program 2Health News:Peapod Expands NutriFilter Shopping Tool With Healthy Ideas Program 3Health News:2 Hours Glued to TV Doubles Kids' Asthma Risk 2Health News:'Conversations with Self: Discovering the Power of Your Inner Voice': Discover How to Find and Listen to an Inner Voice That Is Encouraging and Helpful 2Health News:Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction 2Health News:Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction 3
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: